Selling Health Data

Abstract: Two court cases that involve selling prescription data for pharmaceutical marketing affect biomedical informatics, patient and clinician privacy, and regulation. Sorrell v. IMS Health Inc. et al. in the United States and R v. Department of Health, Ex Parte Source Informatics Ltd. in the United Kingdom concern privacy and health data protection, data de-identification and reidentification, drug detailing (marketing), commercial benefit from the required disclosure of personal information, clinician privacy and the duty of confidentiality, beneficial and unsavory uses of health data, regulating health technologies, and considering data as speech. Individuals should, at the very least, be aware of how data about them are collected and used. Taking account of how those data are used is needed so societal norms and law evolve ethically as new technologies affect health data privacy and protection.

[1]  Jane R. Bambauer,et al.  Is Data Speech , 2014 .

[2]  Carmine Ornaghi,et al.  Competition in the Pharmaceutical Industry: How Do Quality Differences Shape Advertising Strategies? , 2010, Journal of health economics.

[3]  Mark A. Rothstein,et al.  The Hippocratic Bargain and Health Information Technology , 2010, Journal of Law, Medicine & Ethics.

[4]  Simon Chalton.  The Transposition into UK Law of EU Directive 95/46/EC (the Data Protection Directive) , 1997 .

[5]  Linda D. Koontz.  Information Privacy in the Evolving Healthcare Environment , 2013 .

[6]  Wolter Pieters,et al.  Privacy and Information Technology , 2014 .

[7]  Behavioral Domains,et al.  Capturing Social and Behavioral Domains in Electronic Health Records , 2014 .

[8]  K. Schulman,et al.  Ownership of medical information. , 2009, JAMA.

[9]  Daniel M. Hartung,et al.  Effect of Drug Sample Removal on Prescribing in a Family Practice Clinic , 2010, The Annals of Family Medicine.

[10]  Joanna Abadie,et al.  European Data Protection Supervisor , 2016 .

[11]  Bonnie Kaplan,et al.  How Should Health Data Be Used? , 2016, Cambridge Quarterly of Healthcare Ethics.

[12]  R A Miller,et al.  Ethical and legal issues related to the use of computer programs in clinical medicine. , 1985, Annals of internal medicine.

[13]  Kenneth W. Goodman.  Health Information Technology: Challenges in Ethics, Science, and Uncertainty , 2009 .

[14]  D. Beyleveld,et al.  Betrayal of Confidence in the Court of Appeal , 2000, Medical law international.

[15]  K. Himma.  The Handbook of Information and Computer Ethics , 2007 .

[16]  M. Taylor.  Health research, data protection, and the public interest in notification. , 2011, Medical law review.

[17]  Paul M. Schwartz,et al.  The PII Problem: Privacy and a New Concept of Personally Identifiable Information , 2011 .

[18]  S. Findlay.  Direct-to-consumer promotion of prescription drugs. Economic implications for patients, payers and providers. , 2001, PharmacoEconomics.

[19]  Bradley Malin,et al.  Biomedical data privacy: problems, perspectives, and recent advances , 2013, J. Am. Medical Informatics Assoc..

[20]  David Orentlicher.  Prescription Data Mining and the Protection of Patients' Interests , 2010, Journal of Law, Medicine & Ethics.

[21]  Matthew Myron,et al.  What Is Privacy , 2009 .

[22]  Frank Pasquale,et al.  Restoring Transparency to Automated Authority , 2011, J. Telecommun. High Technol. Law.

[23]  M. Rothstein.  Currents in Contemporary Bioethics , 2003, Journal of Law, Medicine & Ethics.

[24]  Bonnie Kaplan,et al.  Sorrell v. IMS Health: issues and opportunities for informaticians , 2013, J. Am. Medical Informatics Assoc..

[25]  L. Ciaccia,et al.  The Immortal Life of Henrietta Lacks , 2010, The Yale Journal of Biology and Medicine.

[26]  Mark A. Rothstein,et al.  Compelled Authorizations for Disclosure of Health Records: Magnitude and Implications , 2007, The American journal of bioethics : AJOB.

[27]  B. Evans.  Much Ado About Data Ownership , 2011 .

[28]  H. Humphrey,et al.  Standards for privacy of individually identifiable health information. , 2003, Health care law monthly.

[29]  Laura A. Levit,et al.  Beyond the HIPAA Privacy Rule: Enhancing Privacy, Improving Health Through Research. Washington, DC: National Academies Press , 2009 .

[30]  Deven McGraw,et al.  Building public trust in uses of Health Insurance Portability and Accountability Act de-identified data , 2013, J. Am. Medical Informatics Assoc..

[31]  Paul Ohm.  Broken Promises of Privacy: Responding to the Surprising Failure of Anonymization , 2009 .

[32]  Barry B Perlman.  Prescriptions, privacy, and the first amendment. , 2011, The New England journal of medicine.

[33]  Yaron F. Dunkel.  Medical Privacy Rights in Anonymous Data: Discussion of Rights in the United Kingdom and the United State in Light of the Source Informatics Cases , 2001 .

[34]  Tamara R. Piety.  Brandishing the First Amendment: Commercial Expression in America , 2012 .

[35]  Julie M Donohue,et al.  A decade of direct-to-consumer advertising of prescription drugs. , 2007, The New England journal of medicine.

[36]  Bonnie Kaplan,et al.  Challenges in ethics, safety, best practices, and oversight regarding HIT vendors, their customers, and patients: a report of an AMIA special task force , 2011, J. Am. Medical Informatics Assoc..

[37]  J. Rubenfeld.  The Right of Privacy , 1989 .

[38]  Michelle M Mello,et al.  Restrictions on the use of prescribing data for drug promotion. , 2011, The New England journal of medicine.

[39]  K. Outterson.  Higher First Amendment hurdles for public health regulation. , 2011, New England Journal of Medicine.

[40]  Patricia S. Abril,et al.  Health Privacy in a Techno-Social World: A Cyber-Patient's Bill of Rights , 2009 .

[41]  David A. Kreda,et al.  Health care information technology vendors' "hold harmless" clause: implications for patients and clinicians. , 2009, JAMA.